Therapeutics: Exonhit seeking partner for Alzheimer’s drug following successful trial

Collaboration opportunity

French therapeutics and diagnostics company Exonhit is looking for a partner to commercialise its Alzheimer’s disease treatment EHT 0202 after reporting successful Phase IIa results.

The trial showed the product is safe and generally well tolerated in patients, and that it could potentially enhance cognition in Alzheimer’s disease patients.

“EHT 0202 has an original mechanism of action with potential disease-modifying and symptomatic properties. The Phase IIa safety results and the potential efficacy signals observed in Alzheimer patients support advancing EHT 0202 into later stage clinical development to collect further evidence of safety and efficacy in a larger number of patients and over a longer time period,” said Bruno Vellas, the principal investigator.

“We are very happy about these promising findings as EHT 0202 could become a new approach to the treatment of Alzheimer’s disease,” said Loïc Maurel, President of ExonHit Therapeutics. “ExonHit will now actively look for a partner to ensure rapid clinical development and commercialisation of EHT 0202.”